These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 26458315)

  • 41. RNA binding motif protein 3 (RBM3) drives radioresistance in nasopharyngeal carcinoma by reducing apoptosis via the PI3K/AKT/Bcl-2 signaling pathway.
    Ma R; Zhao LN; Yang H; Wang YF; Hu J; Zang J; Mao JG; Xiao JJ; Shi M
    Am J Transl Res; 2018; 10(12):4130-4140. PubMed ID: 30662656
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.
    Chiarini F; Grimaldi C; Ricci F; Tazzari PL; Evangelisti C; Ognibene A; Battistelli M; Falcieri E; Melchionda F; Pession A; Pagliaro P; McCubrey JA; Martelli AM
    Cancer Res; 2010 Oct; 70(20):8097-107. PubMed ID: 20876803
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
    Kim A; Park S; Lee JE; Jang WS; Lee SJ; Kang HJ; Lee SS
    Leuk Res; 2012 Jul; 36(7):912-20. PubMed ID: 22560334
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
    Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.
    Dogan Turacli I; Ozkan AC; Ekmekci A
    Tumour Biol; 2015 Dec; 36(12):9339-45. PubMed ID: 26108998
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma.
    Seront E; Rottey S; Filleul B; Glorieux P; Goeminne JC; Verschaeve V; Vandenbulcke JM; Sautois B; Boegner P; Gillain A; van Maanen A; Machiels JP
    BJU Int; 2016 Sep; 118(3):408-15. PubMed ID: 26779597
    [TBL] [Abstract][Full Text] [Related]  

  • 48. nm23 regulates decidualization through the PI3K-Akt-mTOR signaling pathways in mice and humans.
    Zhang X; Fu LJ; Liu XQ; Hu ZY; Jiang Y; Gao RF; Feng Q; Lan X; Geng YQ; Chen XM; He JL; Wang YX; Ding YB
    Hum Reprod; 2016 Oct; 31(10):2339-51. PubMed ID: 27604954
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Decreased miR-146a expression in acute ischemic stroke directly targets the Fbxl10 mRNA and is involved in modulating apoptosis.
    Li SH; Chen L; Pang XM; Su SY; Zhou X; Chen CY; Huang LG; Li JP; Liu JL
    Neurochem Int; 2017 Jul; 107():156-167. PubMed ID: 28202285
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines.
    Masuda M; Shimomura M; Kobayashi K; Kojima S; Nakatsura T
    Oncol Rep; 2011 Nov; 26(5):1273-9. PubMed ID: 21725613
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SETD1A promotes the proliferation and glycolysis of nasopharyngeal carcinoma cells by activating the PI3K/Akt pathway.
    Huang J; Fang J; Xu X; Qian X; Zhang X
    Open Med (Wars); 2022; 17(1):1849-1859. PubMed ID: 36475064
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Qing Yan Li Ge Tang, a Chinese Herbal Formula, Induces Autophagic Cell Death through the PI3K/Akt/mTOR Pathway in Nasopharyngeal Carcinoma Cells In Vitro.
    Yang CH; Tung KL; Wu YT; Liu C; Lin SC; Yang CC; Wu CH; Chang HY; Wu SY; Huang BM; Lan YY
    Evid Based Complement Alternat Med; 2021; 2021():9925684. PubMed ID: 34765012
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Small biomarkers with massive impacts: PI3K/AKT/mTOR signalling and microRNA crosstalk regulate nasopharyngeal carcinoma.
    Li HL; Deng NH; He XS; Li YH
    Biomark Res; 2022 Jul; 10(1):52. PubMed ID: 35883139
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Traditional Herbal Formula NPC01 Exerts Antiangiogenic Effects through Inhibiting the PI3K/Akt/mTOR Signaling Pathway in Nasopharyngeal Carcinoma Cells.
    Yanwei L; Yinli Y; Pan Z
    Evid Based Complement Alternat Med; 2018; 2018():5291517. PubMed ID: 29636781
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Knockout of the placenta specific 8 gene radiosensitizes nasopharyngeal carcinoma cells by activating the PI3K/AKT/GSK3β pathway.
    Yang R; Tao ZZ; Huang ML; Zheng YF; Dai MY; Zou Y; Chen SM
    Am J Transl Res; 2018; 10(2):455-464. PubMed ID: 29511439
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of galactosamine-(N-acetyl)-6-sulfatase (GALNS) as a novel therapeutic target in progression of nasopharyngeal carcinoma.
    Zhang J; Ran H; Wang Z; Liu P; Kang C; Zeng X; Qiu S; Zhang P
    Discov Oncol; 2023 Sep; 14(1):171. PubMed ID: 37707658
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An orthotopic model of metastatic nasopharyngeal carcinoma and its application in elucidating a therapeutic target that inhibits metastasis.
    Smith PA; Merritt D; Barr L; Thorley-Lawson DA
    Genes Cancer; 2011 Nov; 2(11):1023-33. PubMed ID: 22737268
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Retraction Note: The PI3K/mTOR Dual Inhibitor BEZ235 Nanoparticles Improve Radiosensitization of Hepatoma Cells Through Apoptosis and Regulation DNA Repair Pathway.
    Tang X; Li A; Xie C; Zhang Y; Liu X; Xie Y; Wu B; Zhou S; Huang X; Ma Y; Cao W; Xu R; Shen J; Huo Z; Cai S; Liang Y; Ma D
    Nanoscale Res Lett; 2021 Dec; 16(1):179. PubMed ID: 34914025
    [No Abstract]   [Full Text] [Related]  

  • 59. Expression of Concern:
    Artif Cells Nanomed Biotechnol; 2020 Dec; 48(1):717. PubMed ID: 32180459
    [No Abstract]   [Full Text] [Related]  

  • 60. Author Correction: miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K/AKT-c-JUN.
    Zhao M; Luo R; Liu Y; Gao L; Fu Z; Fu Q; Luo X; Chen Y; Deng X; Liang Z; Li X; Cheng C; Liu Z; Fang W
    Nat Commun; 2021 May; 12(1):2997. PubMed ID: 33990567
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.